argenx SE (argenx SE) Days Sales Outstanding

: 93.75 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

argenx SE's average Accounts Receivable for the three months ended in Dec. 2023 was $418 Mil. argenx SE's Revenue for the three months ended in Dec. 2023 was $407 Mil. Hence, argenx SE's Days Sales Outstanding for the three months ended in Dec. 2023 was 93.75.

The historical rank and industry rank for argenx SE's Days Sales Outstanding or its related term are showing as below:

ARGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.06 Med: 46.34 Max: 124.17
Current: 95.47

During the past 13 years, argenx SE's highest Days Sales Outstanding was 124.17. The lowest was 9.06. And the median was 46.34.

ARGX's Days Sales Outstanding is ranked worse than
63.92% of 887 companies
in the Biotechnology industry
Industry Median: 72.76 vs ARGX: 95.47

argenx SE's Days Sales Outstanding declined from Dec. 2022 (126.39) to Dec. 2023 (93.75).

argenx SE Days Sales Outstanding Historical Data

The historical data trend for argenx SE's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

59.57

113.52

10.40

119.65

98.11

argenx SE Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																126.39	100.45	102.61	84.18	93.75

Competitive Comparison

For the Biotechnology subindustry, argenx SE's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

argenx SE Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, argenx SE's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where argenx SE's Days Sales Outstanding falls into.

argenx SE Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

argenx SE's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (241.228	+	417.994)	/	2 )	/	1226.316	*	365
=	329.611					/	1226.316	*	365
=	98.11

argenx SE's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	417.994)	/	1 )	/	406.837	*	365 / 4
=	417.994					/	406.837	*	365 / 4
=	93.75

argenx SE (NAS:ARGX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

argenx SE Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of argenx SE's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE (argenx SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.